ClinicalTrialsFinder

Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma Clinical Trials in Tianjin

1 recruitingTianjin, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658